Notably, the fusion of LDM to hIMB1636 mAb improved the tolerability and tumor-therapeutic efficacy of LDM in nude mice, and suggesting that hIMB1636-LDP-AE may constitute a promising therapeutic candidate against Trop2-expressing tumors. This evidence concerns the gene TACSTD2 and neoplasm.